Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2017

View Archived Issues

FDA awards orphan drug status to SPR-001 for congenital adrenal hyperplasia

National Cancer Center Japan testing DS-8201 in uterine carcinosarcoma

Clementia initiates phase III study of palovarotene for fibrodysplasia ossificans progressive

Novel ex vivo cell and gene therapy regenerates entire human epidermis in patient with JEB

Low-dose LMTM monotherapy may improve Alzheimer's disease impairments

Positive data reported from immunotherapy combination study of DPX-Survivac

Pimozide stabilizes neuromuscular junction transmission in patients with ALS

ChemomAb raises funds to support development of lead product

Janssen Biotech exercises option to collaborate with Idorsia on aprocitentan

Nexus BioPharma licenses rights to KV-001 for rapid reduction of adipose tissue

ObsEva begins proof-of-concept trial of OBE-022

Phase III data show efficacy of LMWF-5A in severe knee osteoarthritis

TAK-935/OV-935 obtains orphan drug status in U.S. for Dravet syndrome

First patient dosed in Novan's phase Ib study of SB-414 in atopic dermatitis

New phase I/II trial to study abexinostat with ibrutinib in relapsed or refractory DLBCL or MCL

Galectin Therapeutics reports positive results from phase IIb study of GR-MD-02

FDA approves Novo Nordisk's Ozempic for type 2 diabetes

National University of Singapore and Academia Sinica patent dual JAK-2/HDAC6 inhibitors

Novel anti-TSHR chimeric antigen receptors identified at the University of Florida

Exicure presents novel antisense oligonucleotides targeteing IL-17RA

Phase II study of MGL-3196 in NASH meets primary endpoint

Shire enters agreement with Rani Therapeutics to study Rani Pill technology

FDA grants orphan drug designation to STP-705 for cholangiocarcinoma

FDA grants full approval to Avastin for recurrent glioblastoma in adults

FDA grants priority review for rucaparib sNDA for maintenance therapy in ovarian cancer

Novartis commences tender offer for Advanced Accelerator Applications

VE-303 begins first-in-human study, awarded U.S. orphan drug designation

New phase I trial studies DNX-2401 in pediatric diffuse intrinsic pontine glioma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...